menu
    • menu
    [{"orgOrder":0,"company":"Biomay","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRIA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"BM32","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Biomay","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biomay \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomay \/ Undisclosed"},{"orgOrder":0,"company":"Biomay","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRIA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"BM32","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Biomay","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biomay \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomay \/ Undisclosed"},{"orgOrder":0,"company":"Biomay","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRIA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"BM32","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Biomay","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Biomay \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomay \/ Undisclosed"},{"orgOrder":0,"company":"Biomay","sponsor":"Medical University of Vienna","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRIA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"BM32","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Biomay","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Biomay \/ Medical University of Vienna","highestDevelopmentStatusID":"8","companyTruncated":"Biomay \/ Medical University of Vienna"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Marinomed Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Marinomed Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Marinomed Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Marinomed Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Apeptico","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRIA","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Solnatide","moa":"peptides","graph1":"Immunology","graph2":"Phase II","graph3":"Apeptico","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Apeptico \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apeptico \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Marinomed Biotech

                            Austria arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Marinomed Biotech

                            Austria arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Last Patient Completes Marinomed Biotech AG’s Phase II Clinical Trial of Tacrosolv to Treat Ocular Hay Fever...

                            Details : Tacrosolv is an improved formulation of tacrolimus, an immunomodulator that can suppress inflammatory reactions, including allergic symptoms. Tacrosolv promises higher bioavailability for local treatment of ocular inflammation.

                            Product Name : Tacrosolv

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            April 12, 2021

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Marinomed Biotech

                            Austria arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Marinomed Biotech

                            Austria arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Marinomed Biotech AG Enrolls First Patients in Phase II Clinical Trial of Tacrosolv to Treat Allergic Rhinocon...

                            Details : The ongoing randomized, placebo controlled, crossover, double-blind, single site Phase II clinical trial is testing Tacrosolv, an improved formulation of tacrolimus, in adult subjects who are suffering from grass pollen induced allergic rhinoconjunctivit...

                            Product Name : Tacrosolv

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            March 11, 2021

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Biomay

                            Austria arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Biomay

                            Austria arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BM32

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Different Pre-seasonal BM32 Dosings on the Induction of a Protective Immune Response

                            Details : BM32 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hypersensitivity.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 31, 2015

                            Lead Product(s) : BM32

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Apeptico

                            Austria arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Apeptico

                            Austria arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solnatide

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study in Intensive Care Patients Regarding the Effect of Inhaled AP-301 After Primary Graft Dysfunction After ...

                            Details : AP-301 is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Graft Rejection.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            March 26, 2014

                            Lead Product(s) : Solnatide

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Biomay

                            Austria arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Biomay

                            Austria arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BM32

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase II Study of Grass Pollen Allergy Vaccine BM32

                            Details : BM32 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rhinitis, Allergic, Seasonal.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 27, 2012

                            Lead Product(s) : BM32

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Biomay

                            Austria arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Biomay

                            Austria arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BM32

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Dose Finding Trial of BM32 in Subjects Suffering From Grass Pollen Allergy

                            Details : BM32 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rhinitis, Allergic, Seasonal.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 03, 2011

                            Lead Product(s) : BM32

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth